ERG Components in Schizophrenia and Bipolar Disorder Type I
Public ClinicalTrials.gov record NCT03788811. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Assessment of ERG Components to Discriminate Between Schizophrenia and Bipolar Disorder Type I
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study will further assess ERG components obtained with different ERG devices, to be considered in a prediction model for each diagnosis. The prediction models are diaMentis proprietary software used as an ERG-based diagnostic test (classified as a Software as Medical Device, SaMD) to support the diagnosis of schizophrenia and bipolar disorder type I. They involve the processing and analysis of specific retinal biosignatures (RSPA) with the support of statistical and mathematical modelling processes e.g. machine learning and statistical learning.
Study identification
- NCT ID
- NCT03788811
- Recruitment status
- Active, not recruiting
- Study type
- Observational
- Phase
- Not listed
- Enrollment
- 300 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 50 Years
- Sex
- All
- Healthy volunteers
- Accepts healthy volunteers
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 4, 2018
- Primary completion
- Dec 30, 2026
- Completion
- Dec 30, 2026
- Last update posted
- Aug 21, 2025
2018 – 2026
United States locations
- U.S. sites
- 11
- U.S. states
- 6
- U.S. cities
- 11
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Collaborative Neuroscience Research LLC | Garden Grove | California | 92845 | — |
| Synergy San Diego | Lemon Grove | California | 91945 | — |
| Collaborative Neuroscience Research LLC | Torrance | California | 90502 | — |
| Segal trials West Broward Outpatient Site | Lauderhill | Florida | 33319 | — |
| Segal Trials Miami Lakes Medical Research | Miami Lakes | Florida | 33016 | — |
| McLean Hospital | Belmont | Massachusetts | 02478 | — |
| Rutgers University Behavioral HealthCare | Piscataway | New Jersey | 08854 | — |
| The Zucker Hillside Hospital | Glen Oaks | New York | 11004 | — |
| University of Rochester Medical Center | Rochester | New York | 14642 | — |
| Richmond Behavioral Associates | Staten Island | New York | 10314 | — |
| University Hills Clinical Research | Irving | Texas | 75062 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 8 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03788811, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 21, 2025 · Synced Sep 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03788811 live on ClinicalTrials.gov.